Phototherapy

Apremilast Therapeutic Cheat Sheet
apremilast
by Alexis Carrington, MD on
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica …
Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
Tofacitinib
by NEXT STEPS IN DERM TEAM on
INTRODUCTION Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
Diagnosing & Treating Vitiligo in 2022 and What’s To Come
vitiligo
by Shanthi Narla, MD on
As a former vitiligo clinical trials research fellow, I have attended more than my fair share of presentations on vitiligo. Yet, I am amazed at how each additional lecture continues to teach me new and exciting concepts and treatment options for vitiligo. Dr. Seemal Desai’s lecture at the 2022 Skin of Color Update Conference was no exception to this rule. During the SOCU Conference held in Ne …
Pediatric Scaling Diseases: An Approach to Pediatric Psoriasis
Pediatric Psoriasis
by Jacqueline McKesey, MD, MS on
Dr. Lawrence F. Eichenfield, meeting co-chair for the 17th Annual Women’s and Pediatric Dermatology Seminar, kicked off session III with a superb talk titled “Scaling the Heights…and Below, Pediatric Scaling Diseases: Psoriasis and Others”,  giving us a bird’s eye view on the old and the new regarding pediatric psoriasis. Dr. Eichenfield is a complete rock star and served as a valued …
Chromate-Induced Allergic Contact Dermatitis Treated With Dupilumab
Chromate-Induced Allergic Contact Dermatitis Treated With Dupilumab
by NEXT STEPS IN DERM TEAM on
Chromate causes persistent, difficult to treat irritant and allergic contact dermatitis in cement-handling occupational workers. When therapeutics such as topical corticosteroids, topical calcineurin inhibitors, phototherapy and immune-modulating treatments like methotrexate fail, many patients are advised that avoidance may be the only remaining option – an option that may be particularly chall …